Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of endometriosis, published as a controlled clinical trial.

The researchers attempt to investigate the interaction of metformin, insulin-like growth factor 1 (IGF-1) expression, and phosphorylated mammalian target of rapamycin (p-mTOR) and AMP-activated protein kinase (p-AMPK).

Why It Was Studied

Metformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus.

However, its cellular and molecular mechanisms of anticancer action in the endometrial cancer (EC) have not yet been fully elucidated.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, women only.

Sixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis.

Thirty healthy donors are control groups.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger IGF-1 LR3 study would be practical.

What Was Measured

The subject headings attached to it are AMP-Activated Protein Kinases, Carcinoma, Endometrial Neoplasms, Endometrium, Hypoglycemic Agents, Insulin-Like Growth Factor I and Metformin.

What This Means in Plain Language

The paper is a pilot study of IGF-1 LR3 in people with endometriosis.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society), a journal based in United States.

More context: the IGF-1 LR3 compound page, Endometriosis research.